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After surviving cancer, what about late
life effects of the cure?
Julie Nonnekens & Jan HJ Hoeijmakers
The widely used chemotherapeutic
cisplatin causes ototoxicity as late-term
side effect. In this issue, Benkafadar et al
(2017) decipher the mechanism of cisplatin-
induced ototoxicity and provide evidence
that transient inhibition of p53 ameliorates
ototoxicity without influencing chemother-
apeutic efficacy. These findings may open
exciting perspectives for reducing (late-
term) side effects of cancer treatment.
See also: N Benkafadar et al (January 2017)
C isplatin (CDDP) is a frequentlyemployed chemotherapeutic drugboth in curative and palliative
settings. When cancer patients are cured due
to CDDP therapy, they unfortunately often
experience severe long-term side effects
including irreversible hearing loss (ototoxic-
ity) and permanent neuronal and renal
damage. CDDP targets the DNA by biva-
lently reacting with purine bases mainly G
residues, generating inter- and intra-strand
crosslinks (Fig 1) (Fram, 1992). These
adducts disrupt DNA helical structure, acti-
vate the DNA damage response (DDR), and
interfere with vital DNA transactions,
obstructing transcription and replication.
Particularly inter-strand cross-links, prevent-
ing strand separation, are highly toxic in
proliferating cells, which includes tumor
cells but also normal tissues in the body.
Handling of these lesions by cellular repair
systems or upon blocking transcription and
replication may result in the formation of
DNA double-strand breaks and other detri-
mental DNA intermediates. In replicating
cells (inadequate) repair of CDDP lesions
may lead to mutations (base substitutions
and chromosomal aberrations), which
hamper cell function and contribute to
secondary tumors later in life. In non-prolif-
erating cells, it is likely that persisting inter-
and intra-strand cross-links or irreparable
double-strand breaks cause chronic activa-
tion of the DDR and enduring, local suppres-
sion of gene expression, affecting cell
function. The DDR is triggered by several
signaling proteins such as Ataxia telangiec-
tasia mutated (ATM) and AT- and rad3-
related (ATR) that are recruited to the site
of DNA damage where they initiate a
cascade of local chromatin modifications
acting as a platform for binding of numer-
ous repair proteins to facilitate repair.
Simultaneously, downstream proteins
promote transient cell cycle arrest and, in
case of failing repair, cell death via apopto-
sis or necroptosis, or cellular senescence
which may lead to cellular dysfunction and
genome instability. The tumor suppressor
protein p53 is a key player in these deci-
sions, responsible for most of these
outcomes, which influence long-term effects
(Fig 1) (Jackson & Bartek, 2009).
These late life events consequent to
anticancer treatment include cardiac, hear-
ing, vision, respiratory, and renal problems,
all resembling aspects of aging in a prema-
ture manner (Armstrong et al, 2014). In
addition, cancer survivors display other
signs of accelerated aging, such as fatigue
and physical and memory impairment (Mac-
cormick, 2006). This is in line with increas-
ing evidence for a strong link between
accumulating DNA damage and acceleration
of aging (Hoeijmakers, 2009). For instance,
chronic exposure of mice to a low dose of
gamma irradiation accelerates aging. Also
most human progeroid syndromes are due
to mutations in genome stability genes,
specifically DNA damage repair pathways.
Similarly, mouse models with defects in
DNA repair and response systems that
primarily protect from the cytotoxic or cyto-
static effects of DNA damage display many
bona fide features of accelerated aging in
multiple organs and tissues at histopatholog-
ical, physiological, hormonal, and functional
levels (Hoeijmakers, 2009).
Ototoxicity by CDDP is caused by degen-
eration of neuro-sensory epithelium of the
cochlea mostly by damage to the outer hair
cells (OHCs). Until now, no molecular path-
way underlying the CDDP-induced ototoxic-
ity has been described. In this issue,
Benkafadar et al (2017) show that the ATM-
Chk2-p53 axis of the DDR is highly activated
in OHCs after CDDP exposure. Interestingly,
targeting this pathway in mice using a
genetic approach or a pharmacological inhi-
bitor of p53 (Pifithrin-a or PFT-a) preserves
hearing function by preventing cochlear cell
death (Benkafadar et al, 2017), showing
that influencing the DDR can diminish long-
term consequences and keeping OHCs alive
after CDDP treatment may reduce hearing
loss. Importantly, the authors also show
that inhibition of p53 using PFT-a did not
go at the expense of chemotherapeutic effi-
cacy. These findings can have important
implications for reducing side effects of
cisplatin and likely other cancer therapies
based on injuring DNA. Late life damage to
other tissues is most likely also mediated
via the DDR including p53. Application of
PFT-a might therefore not only improve
hearing abilities, but also diminish other
side effects as nephrotoxicity and neurotoxi-
city. However, genome instability caused by
chemotherapy may also cause secondary
malignancies (Fig 1). Transient inhibition of
the p53 pathway might increase this risk,
and therefore, it is critical to study this in
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detail. Another aspect related to DNA
damage and p53 activity is accumulation of
senescent cells in many tissues due to
chemotherapy. These persistent cells, carry-
ing irreparable DNA damage, exhibit a
so-called senescence-associated secretory
phenotype (SASP), excreting numerous
factors, including a litany of pro-inflamma-
tory cytokines, such as IL-6, IL-8, IL-1a,
TNFb, and others (Childs et al, 2015),
which likely has systemic effects and may
contribute to, for example, fatigue often
observed after chemotherapy. Recently,
selective elimination of senescent cells,
which also accumulate in normal aging, has
been reported to improve several health
parameters in mice (Childs et al, 2015). It
will be important to determine what
happens to senescence and to fatigue after
transient p53 inhibition.
In a wider context, tissue differences in
metabolism (including enzymatic processing
of the agent), pharmacokinetics, prolifera-
tive versus post-mitotic status, perfusion,
blood–brain barrier, and efficacy of the DDR
contribute to heterogeneity in response to
chemotherapy next to genetic (e.g., ethnic)
differences. Several of these parameters are
also influenced by hormonal (e.g., gender)
and immune status, age and even circadian
time. For instance, upon aging, the p53
response gets down-regulated in many
tissues (Feng et al, 2007), influencing
response to chemo- and radiotherapy. An
important not yet generally appreciated
factor, with significant therapeutic implica-
tions is nutrition. Various recent studies
have shown that in particular dietary
restriction (DR, i.e., reduction in food
intake without malnutrition) or short-term
fasting may have remarkable clinical poten-
tial in reducing short- and perhaps long-
term side effects. DR is for long known to
extend life span in numerous species by
redirecting energy resources from growth to
maintenance and defense mechanisms,
including stress resistance and antioxidant
systems. DR has been shown to reduce
damage due to ischemia–reperfusion, and
currently, clinical trials are ongoing to
examine whether it also reduces short- and
long-term side effects of chemotherapy
without compromising anticancer efficacy
(Brandhorst & Longo, 2016). Also inhibitors
of necroptosis may have a potential to
reduce short- and long-term side effects
(Matt & Hofmann, 2016). It might be inter-
esting to examine these interventions in
combination with transient inhibition of
p53.
In summary, CDDP treatment causes
many severe (late stage) side effects that
are tissue specific and resemble acceler-
ated aging. Pharmacological inhibition of
p53 and other interventions might signifi-
cantly reduce side effects, thereby signifi-
cantly improving quality of life of cancer
patients.
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Figure 1. Factors influencing short- and long-term effects of cisplatin.
Overview of how different factors can influence long-term normal tissue effects after cisplatin (CDDP) treatment.
CDDP causes DNA damage. Many cellular effects are mediated by p53 as part of the DNA damage response
yielding long-term side effects. Factors such as tissue differences (metabolism, pharmacokinetics, proliferative
status, and DNA damage response) and systemic differences (nutritional status, hormones, immunological
effects, age, ethnicity, etc.) influence these side effects, which resemble accelerated aging (ototoxicity,
neurotoxicity, and nephrotoxicity) and/or increase cancer (secondary malignancies). p53 inhibition using PFT-a
and likely dietary restriction might reduce at least part of these side effects.
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